Global Infertility Services Market Growth (Status and Outlook) 2025-2031

The global Infertility Services market size is predicted to grow from US$ 7531 million in 2025 to US$ 11740 million in 2031; it is expected to grow at a CAGR of 7.7% from 2025 to 2031.

Infertility services refer to medical procedures and treatments that are designed to help individuals or couples who are experiencing difficulties in conceiving a child. These services aim to diagnose and treat the underlying causes of infertility, and potentially assist in achieving a successful pregnancy.

Infertility services have become an important part of the global medical field in recent years. With the change of lifestyle, the influence of environmental factors and the change of fertility concepts, infertility has gradually become an important social and health issue worldwide. According to statistics from the World Health Organization (WHO), about 10-15% of couples in the world face infertility problems. This proportion varies in different countries and regions, but the prevalence of this problem has prompted the rapid development of the infertility treatment market.

At present, the scale of the infertility service market is growing globally and is expected to continue to grow in the next few years. The rapid development of assisted reproductive technology (ART) has given hope to many couples who were once unable to get pregnant. The maturity of technologies such as in vitro fertilization (IVF), egg freezing, intracytoplasmic sperm injection (ICSI), and embryo genetic screening (PGS/PGD) has not only increased the success rate, but also allowed more infertile patients to enjoy treatment. In addition, with the advancement of genetic testing technology, the popularization of preimplantation genetic screening can effectively reduce the risk of chromosomal abnormalities and increase the chance of successful pregnancy.

Despite the rapid growth of the infertility service market, it still faces some challenges and problems:

High treatment costs: Assisted reproductive technologies such as IVF are expensive and not all families can afford them. Especially in some developing countries or regions, although the technology is gradually becoming popular, the cost of treatment is still a major obstacle. Therefore, how to reduce treatment costs and provide more economical treatment options is still a difficult problem that needs to be solved. Differences in technology accessibility: Although some advanced assisted reproductive technologies have been popularized in some developed countries, in many developing countries and regions, these technologies are not yet popular and the accessibility of treatment is low. In addition, the imbalance of medical facilities has caused a gap in the treatment of infertility in patients in different regions and industries.

With the continuous advancement of science and technology and the increase in social needs, the future development trend of the infertility service market is becoming clearer and clearer.

The core manufacturers of global infertility services include Ferring Pharmaceuticals, Merck, Jinxin Fertility, Vitrolife, Mayo Clinic and LIVZON. The top three manufacturers account for approximately 24% of the global share. The Asia-Pacific region is the world's largest market, accounting for nearly 45% of the market share.

In terms of product type, assisted reproductive technology (ART) occupies a dominant position, accounting for 62% of the market share. At the same time, in terms of application, females are the largest application field, accounting for 66%.

LPI (LP Information)' newest research report, the “Infertility Services Industry Forecast” looks at past sales and reviews total world Infertility Services sales in 2024, providing a comprehensive analysis by region and market sector of projected Infertility Services sales for 2025 through 2031. With Infertility Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Infertility Services industry.

This Insight Report provides a comprehensive analysis of the global Infertility Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Infertility Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Infertility Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Infertility Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Infertility Services.

This report presents a comprehensive overview, market shares, and growth opportunities of Infertility Services market by product type, application, key players and key regions and countries.

Segmentation by Type:
Assisted Reproductive Technology (ART)
Infertility Drug Services
Others

Segmentation by Application:
Male
Female

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Ferring Pharmaceuticals
Merck
Jinxin Fertility
Vitrolife
Mayo Clinic
LIVZON
Abbott
Monash IVF
CARE Facility
Theramex
TriHealth
NMC Health
CooperSurgical
Irvine Scientific
Virtus Health
CinnaGen
OB GYN Associates
Caerus Biotech
InVitroCare
INVO Bioscience

Please note: The report will take approximately 2 business days to prepare and deliver.